

Current Report No 27/2022

Concluding an agreement with a transaction advisor

With reference to ESPI Report 22/2022 of 7 September 2022, the Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wrocław, Poland, hereby reports that on 30 November 2022, Company signed an agreement with Clairfield Partners LLC, headquartered in New York (the "Advisor", Clairfield), to provide advisory services in connection with the planned partnership, license, and / or sale of part or all of its intellectual property and related technology.

Clairfield will be responsible for identifying and selecting potential buyers and partners. These activities will include, preparing the necessary materials and establishing contacts i.a. with global in-vitro diagnostic medical devices companies. In addition, Clairfield will support the Company in organizing the due diligence process, shaping the negotiation strategy, and coordinating the process of final discussions related to the transaction.

Clairfield's services will be provided on an exclusive basis. Remuneration for the services includes a variable part, the so-called success fee, which depends on the result, i.e., the value of the potential transaction, and a fixed part, spread over several monthly payments. The terms of the agreement do not differ from those commonly used in these types of contracts.

Clairfield Partners LLC is part of Clairfield International SA - an international company providing corporate finance services, mainly in the field of mergers and acquisitions, to multinational corporations and financial investors. Clairfield has extensive experience in mergers and acquisitions in the areas of medical technology, biotechnology and molecular diagnostics.

The Issuer will report on the next significant stages of the strategic options review process in current reports.

